Spine

Deputy Minister of Ukraine, Nataliia Kalmykova, will be speaking at the LA Convention Center this week

Retrieved on: 
Tuesday, March 12, 2024
Karma, SBMT, Brain, Congress, Brain mapping, Neuroscience, Neurology, Multiple sclerosis, Alzheimer's disease, Ophthalmology, Doe, Knowledge, Los Angeles Convention Center, Associate, Journal, Loma Linda University, Disease, Military medicine, World Congress, AI, Cadaver, Neuro-oncology, Society, Michelson Medical Research Foundation, Journal of Alzheimer's Disease, NASA, Neuroelectrics, Regenerative medicine, Therapy, Spine, Multimedia, Springer Nature, B cell, Neurosurgery

Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.

Key Points: 
  • Deputy Minister of Ukraine, Nataliia Kalmykova, will be amongst keynotes ; Ukrainian neurosurgeons from the frontline will also be speaking about combat casualty care and participate in the convention in person.
  • Since the beginning of the war in Ukraine, SBMT has been supporting Ukrainian doctors with training and medical equipment.
  • The SBMT World Congress is renowned for its comprehensive program, offering a diverse range of presentations, hands-on workshops, Bioskills cadaver labs, and an expansive exhibition hall.
  • Attendees can expect to engage with cutting-edge research, innovative technologies, and expert insights that are shaping the future of neurosciences and neurotechnology.

Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System

Retrieved on: 
Monday, March 11, 2024
Neurosurgery, Paper, Spine, Journal, Brain

The aim of the study was to evaluate the safety, accuracy, and efficacy of the Prism System.

Key Points: 
  • The aim of the study was to evaluate the safety, accuracy, and efficacy of the Prism System.
  • “Our research presents a comprehensive and meticulously conducted open analysis of the ClearPoint Prism laser system.
  • “This robust, peer-reviewed validation clearly demonstrates that the advantages of Prism result in excellent predictability of targeted cell death.
  • Additionally, the Prism System has been used together with the Company’s recently FDA cleared Array software version 1.2 to improve the practicality of neuro laser therapy.

The Driving Force Company PI Connection™ Introduces VMA® To Local Clinics as Exclusive Provider

Retrieved on: 
Monday, March 4, 2024
Isolate, Spine, DABCO, X-ray, Instability, FDA, Injury, DMX, Radiation, CPC, Health, Personal injury, Patient, Diagnosis

LOMBARD, Ill., March 04, 2024 (GLOBE NEWSWIRE) -- PI Connection™ from The Driving Force Company, https://drivingforcecompany.com , announced today that integrated healthcare clinics nationwide can now offer their patients groundbreaking, proprietary Vertebral Motion Analysis (VMA®) technology in-house.

Key Points: 
  • LOMBARD, Ill., March 04, 2024 (GLOBE NEWSWIRE) -- PI Connection™ from The Driving Force Company, https://drivingforcecompany.com , announced today that integrated healthcare clinics nationwide can now offer their patients groundbreaking, proprietary Vertebral Motion Analysis (VMA®) technology in-house.
  • “Unlike traditional x-rays and digital motion x-rays (DMX), VMA® technology captures real-time video quickly and accurately to detect injuries and instability in the spine,” states Dr. S. Scott Tauber, DC, DABCO, CPC of The Driving Force Company.
  • “It is the cost-effective, easy-to-use technology of the future that will help medical professionals provide better care for their patients.
  • “Several pain management and personal injury clinics have started using the state-of-the-art diagnostics powered by our exclusive VMA® medical equipment to provide better patient care and significantly increase net monthly revenue,” states Sam Frentzas, The Driving Force Company PI Connection Co-Founder.

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

Retrieved on: 
Friday, March 1, 2024
Spine, Telephone, Brain

SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.

Key Points: 
  • SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.
  • Investors and analysts are invited to listen to the live broadcast review of the Company’s 2023 fourth quarter and full year results on Tuesday, March 12th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here .
  • Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.
  • An online archive of the broadcast will be available on the Company’s Investor website at https://ir.clearpointneuro.com

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

Retrieved on: 
Thursday, February 29, 2024
Prospectus, Spine, Suite, Investment, Sale, ATTN:, Form, Security (finance), Form S-3, Research, Brain

SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the pricing of its underwritten public offering of 2,307,694 shares of its common stock at a price to the public of $6.50 per share.

Key Points: 
  • SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the pricing of its underwritten public offering of 2,307,694 shares of its common stock at a price to the public of $6.50 per share.
  • In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 346,154 shares of its common stock at the public offering price less underwriting discounts and commissions.
  • The offering is expected to close on March 4, 2024, subject to customary closing conditions.
  • An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering are available on the SEC website at www.sec.gov.

Synaptive Medical Welcomes Chris Marrus as New Chief Commercial Officer

Retrieved on: 
Thursday, February 29, 2024
Spine, Marketing, Neuro, ENT, History, Health, Raquel C. Bono, Patient, Leica, Intuitive Surgical, Informatics, MRI, Management

Chris Marrus brings extensive experience in innovative med tech to Synaptive having held senior leadership roles at INSIGHTEC, Stryker, MAKO Surgical, Intuitive Surgical and Leica

Key Points: 
  • Chris Marrus brings extensive experience in innovative med tech to Synaptive having held senior leadership roles at INSIGHTEC, Stryker, MAKO Surgical, Intuitive Surgical and Leica
    TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, is proud to announce the appointment of Chris Marrus as Chief Commercial Officer.
  • Chris has a proven track record of spearheading sales initiatives and fostering exponential growth for innovative companies.
  • "Synaptive is thrilled to welcome Chris Marrus to our senior leadership team," stated Cameron Piron, Chief Strategy Officer, President and Founder of Synaptive Medical.
  • "I am thrilled to embark on this journey with Synaptive Medical," commented Chris Marrus, newly appointed Chief Commercial Officer of Synaptive Medical.

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, February 28, 2024
Prospectus, Spine, Suite, Sale, ATTN:, Form, Security (finance), Form S-3, Brain

SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock.

Key Points: 
  • SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock.
  • The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Lake Street Capital Markets, LLC is acting as the sole book-running manager for the proposed offering.

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Retrieved on: 
Wednesday, February 21, 2024
NeuroImage, Spine, FreeSurfer, FDA, Biopsy, Paper, Surgeon, Manuscript, Deep brain stimulation, Brain, Medical device

“The Maestro Brain Model, and its integration into the recently FDA cleared ClearPoint 2.2 navigation software, is our latest example of just that.

Key Points: 
  • “The Maestro Brain Model, and its integration into the recently FDA cleared ClearPoint 2.2 navigation software, is our latest example of just that.
  • The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation.
  • This manuscript introduces the methodology for shape-constrained deformable brain segmentation behind Maestro, describes the validation performed for its FDA clearance, and presents a comparison with manual expert segmentation and FreeSurfer, an open-source segmentation software.
  • Reproducibility error of Maestro (green), FreeSurfer 7.2 (blue) and manual segmentation (red) for common brain structures (left), and average over all structures (right).

Globus Medical Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Philosophy, Spine, Globus Medical, Telephone, ID, Surgeon, NuVasive, GAAP, Webcast, Patient, EPS, Globus, Pharmaceutical industry

AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
  • U.S. net sales for the fourth quarter of 2023 increased by 111.1% compared to the fourth quarter of 2022. International net sales increased by 200.9% over the fourth quarter of 2023 on an as-reported basis, and an increase of 200.8% on a constant currency basis.
  • Diluted EPS for the fourth quarter was $0.11, compared to $0.49 for the fourth quarter of 2022.
  • Globus Medical will hold a teleconference to discuss its 2023 fourth quarter and full year results with the investment community at 4:30 p.m. Eastern Time today.

SurGenTec® Receives FDA Clearance for OsteoFlo® HydroPutty™, a Hydrophilic Synthetic Bone Graft

Retrieved on: 
Thursday, March 7, 2024
Medical Supplies, Medical Devices, FDA, Health, Surgery, Neurology, Minimally invasive procedure, Spine, Multimedia, MD, Blood, Physician, Food, Bone marrow, Baptist Health, Patient

This innovative formulation turns to a putty and offers superior handling characteristics with a resorption profile optimized for bone growth.

Key Points: 
  • This innovative formulation turns to a putty and offers superior handling characteristics with a resorption profile optimized for bone growth.
  • Its unique hydrophilic bonds enable the attachment of growth factors and provide an ideal scaffolding for bone growth.
  • HydroPutty differentiates itself by allowing me to deliver next generation hydrophilic bone graft to maximize fusion in minimally invasive surgery."
  • OsteoFlo HydroPutty provides physicians with a fully synthetic bone graft option, minimizing the risks associated with human tissue.